Literature DB >> 33705884

Differential alternative RNA splicing and transcription events between tumors from African American and White patients in The Cancer Genome Atlas.

Muthana Al Abo1, Terry Hyslop2, Xiaodi Qin3, Kouros Owzar3, Daniel J George4, Steven R Patierno4, Jennifer A Freedman5.   

Abstract

Individuals of African ancestry suffer disproportionally from higher incidence, aggressiveness, and mortality for particular cancers. This disparity likely results from an interplay among differences in multiple determinants of health, including differences in tumor biology. We used The Cancer Genome Atlas (TCGA) SpliceSeq and TCGA aggregate expression datasets and identified differential alternative RNA splicing and transcription events (ARS/T) in cancers between self-identified African American (AA) and White (W) patients. We found that retained intron events were enriched among race-related ARS/T. In addition, on average, 12% of the most highly ranked race-related ARS/T overlapped between any two analyzed cancers. Moreover, the genes undergoing race-related ARS/T functioned in cancer-promoting pathways, and a number of race-related ARS/T were associated with patient survival. We built a web-application, CanSplice, to mine genomic datasets by self-identified race. The race-related targets have the potential to aid in the development of new biomarkers and therapeutics to mitigate cancer disparity.
Copyright © 2021 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  African American; Alternative RNA splicing; Alternative transcription; Breast cancer; Cancer disparity; Prostate cancer; Race; SpliceSeq; Splicing factors; TCGA; White

Mesh:

Year:  2021        PMID: 33705884      PMCID: PMC8205977          DOI: 10.1016/j.ygeno.2021.02.020

Source DB:  PubMed          Journal:  Genomics        ISSN: 0888-7543            Impact factor:   5.736


  92 in total

1.  Dual function of UNC-51-like kinase 3 (Ulk3) in the Sonic hedgehog signaling pathway.

Authors:  Alla Maloverjan; Marko Piirsoo; Lagle Kasak; Lauri Peil; Torben Østerlund; Priit Kogerman
Journal:  J Biol Chem       Date:  2010-07-19       Impact factor: 5.157

Review 2.  The role of alternative splicing in cancer drug resistance.

Authors:  Zahava Siegfried; Rotem Karni
Journal:  Curr Opin Genet Dev       Date:  2017-11-05       Impact factor: 5.578

Review 3.  Alternative pre-mRNA splicing regulation in cancer: pathways and programs unhinged.

Authors:  Charles J David; James L Manley
Journal:  Genes Dev       Date:  2010-11-01       Impact factor: 11.361

Review 4.  Proteasome inhibitors in cancer therapy.

Authors:  Elisabet E Manasanch; Robert Z Orlowski
Journal:  Nat Rev Clin Oncol       Date:  2017-01-24       Impact factor: 66.675

5.  Inositol pyrophosphates promote tumor growth and metastasis by antagonizing liver kinase B1.

Authors:  Feng Rao; Jing Xu; Chenglai Fu; Jiyoung Y Cha; Moataz M Gadalla; Risheng Xu; James C Barrow; Solomon H Snyder
Journal:  Proc Natl Acad Sci U S A       Date:  2015-01-23       Impact factor: 11.205

6.  Silencing of ribosomal protein S9 elicits a multitude of cellular responses inhibiting the growth of cancer cells subsequent to p53 activation.

Authors:  Mikael S Lindström; Monica Nistér
Journal:  PLoS One       Date:  2010-03-08       Impact factor: 3.240

7.  Mapping identifiers for the integration of genomic datasets with the R/Bioconductor package biomaRt.

Authors:  Steffen Durinck; Paul T Spellman; Ewan Birney; Wolfgang Huber
Journal:  Nat Protoc       Date:  2009-07-23       Impact factor: 13.491

Review 8.  Alternative RNA splicing and cancer.

Authors:  Sali Liu; Chonghui Cheng
Journal:  Wiley Interdiscip Rev RNA       Date:  2013-06-13       Impact factor: 9.957

9.  Integrative Analysis Identifies Four Molecular and Clinical Subsets in Uveal Melanoma.

Authors:  A Gordon Robertson; Juliann Shih; Christina Yau; Ewan A Gibb; Junna Oba; Karen L Mungall; Julian M Hess; Vladislav Uzunangelov; Vonn Walter; Ludmila Danilova; Tara M Lichtenberg; Melanie Kucherlapati; Patrick K Kimes; Ming Tang; Alexander Penson; Ozgun Babur; Rehan Akbani; Christopher A Bristow; Katherine A Hoadley; Lisa Iype; Matthew T Chang; Andrew D Cherniack; Christopher Benz; Gordon B Mills; Roel G W Verhaak; Klaus G Griewank; Ina Felau; Jean C Zenklusen; Jeffrey E Gershenwald; Lynn Schoenfield; Alexander J Lazar; Mohamed H Abdel-Rahman; Sergio Roman-Roman; Marc-Henri Stern; Colleen M Cebulla; Michelle D Williams; Martine J Jager; Sarah E Coupland; Bita Esmaeli; Cyriac Kandoth; Scott E Woodman
Journal:  Cancer Cell       Date:  2017-08-14       Impact factor: 31.743

10.  Alternative splicing promotes tumour aggressiveness and drug resistance in African American prostate cancer.

Authors:  Bi-Dar Wang; Kristin Ceniccola; SuJin Hwang; Ramez Andrawis; Anelia Horvath; Jennifer A Freedman; Jacqueline Olender; Stefan Knapp; Travers Ching; Lana Garmire; Vyomesh Patel; Mariano A Garcia-Blanco; Steven R Patierno; Norman H Lee
Journal:  Nat Commun       Date:  2017-06-30       Impact factor: 14.919

View more
  3 in total

1.  Deciphering associations between three RNA splicing-related genetic variants and lung cancer risk.

Authors:  Wenjun Yang; Hongliang Liu; Ruoxin Zhang; Jennifer A Freedman; Younghun Han; Rayjean J Hung; Yonathan Brhane; John McLaughlin; Paul Brennan; Heike Bickeboeller; Albert Rosenberger; Richard S Houlston; Neil E Caporaso; Maria Teresa Landi; Irene Brueske; Angela Risch; David C Christiani; Christopher I Amos; Xiaoxin Chen; Steven R Patierno; Qingyi Wei
Journal:  NPJ Precis Oncol       Date:  2022-06-30

Review 2.  Novel Redirected T-Cell Immunotherapies for Advanced Prostate Cancer.

Authors:  Tanya B Dorff; Vivek Narayan; Stephen J Forman; Peter D Zang; Joseph A Fraietta; Carl H June; Naomi B Haas; Saul J Priceman
Journal:  Clin Cancer Res       Date:  2022-02-15       Impact factor: 13.801

3.  Changing the landscape of non-small cell lung cancer disparities.

Authors:  Joab O Odera; Muthana Al Abo; Steven R Patierno; Jeffrey M Clarke; Jennifer A Freedman
Journal:  J Cancer Biol       Date:  2021
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.